Evaluation of surface contamination in a hospital hematology

Abstract

Objective. To describe environmental contamination with hazardous drugs in a hospital pharmacy setting before and after reorganizing a hematology— oncology satellite pharmacy.

Methods. This is a descriptive study of surface contamination with cyclophosphamide, ifosfamide, and methotrexate in two hematology—oncology satellite pharmacies. In order to measure surface contamination with hazardous drugs, samples from four distinct measurement sites within the pharmacy were taken in each of the two phases (pre-and postphases) using a sampling procedure and an analytical method modified from Larson et al.

Results. A total of 133 samples from four measurement sites were taken and analyzed over the course of the study (specifically 60 prephase samples and 73 postphase samples). The study showed a significant increase in the number of positive samples (from 66.7% to 90.4%, p<0.001) from the pre- to the postphase. The increase, however, is only significant in terms of the location where completed preparations were placed after they had come out from under the hood (from 0/15 to 21/28, p<0.001) and the work surface (from 8/15 to 15/15, p = 0.006) and only in terms of ifosfamide. Furthermore, for the other sites studied, the number of positive samples remained unchanged between the pre- and postphase. A statistically significant difference between the pre- and postphase was observed in terms of ifosfamide for three of the four measurement sites studied and methotrexate for one of the four sites. Average concentrations were higher in the post phase in three of the four cases.

Conclusion. This study describes environmental contamination with hazardous drugs in a hospital pharmacy setting before and after reorganizing a hematology—oncology satellite pharmacy. The study showed that a refitting of the hemato-oncology pharmacy is not a sufficient strategy to reduce the environmental contamination by ifosfamide because a significant increase in the number of positive samples from the pre- to the postphase have been observed. Many factors can contribute to influence the contamination of hazardous drugs such as the workflow and the training of the personal. Continuous environmental surveillance of hazardous drugs is required to document traces and help reduce risks. J Oncol Pharm Practice (2009) 15: 53—61.

Keywords

hazardous drugs cyclophosphamide ifosfamide methotrexate environmental contamination monitoring sampling quantification pharmacy

Get full access to this article

View all access options for this article.

References

Turci R. , Sottani C. , Spagnoli G. , Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 789(2): 169-209.

Acampora A. , Castiglia L. , Miraglia N. et al. A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Ann Occup Hyg 2005; 49(7): 611-618.

Minoia C. , Turci R. , Sottani C. , Schiavi A. , Perbellini L. , Angeleri S. , Draicchio F. , Apostoli P. Application of high performance liquid chromatography/ tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom 1998; 12(20): 1485-93.

Nygren O. Wipe sampling as a tool for monitoring aerosol deposition in workplaces. J Environ Monit 2006; 8(1): 49-52.

Sabatini L. , Barbieri A. , Tosi M. , Violante FS A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. J Mass Spectrom 2005; 40(5): 669-74.

Mason HJ , Blair S. , Sams C. et al. Exposure to antineoplastic drugs in two UK hospital pharmacy units . Ann Occup Hyg 2005; 49(7): 603-10.

Sessink PJ , Anzion RB , Van den Broek PH , Bos RP Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci 1992; 14(1): 16-22.

Connor TH , Sessink PJ , Harrison BR , Pretty JR , Peters BG , Alfaro RM et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health Syst Pharm 2005; 62(5): 475-84.

Sessink PJ , Boer KA , Scheefhals AP , Anzion RB , Bos RP Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health 1992; 64(2): 105-12.

10.

Schulz H. , Bigelow S. , Dobish R. , Chambers C. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective. J Oncol Pharm Practice 2005; 11: 101-09.

11.

Sessink PJ , Wittenhorst BC , Anzion RB , Bos RP Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health 1997; 52(3): 240-44.

12.

Connor TH , Anderson RW , Sessink PJ , Broadfield L. , Power LA Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health Syst Pharm 1999; 56(14): 1427-32.

13.

The United States Pharmacopeial Convention. Pharmaceutical compounding - sterile preparations. Chapter 797, Rockville, 2003.

14.

National Institute for Occupational Safety and Health. NIOSH Alert. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. http://www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf (Accessed 12 October 2005).

15.

American Society of Health-System Pharmacists. Guidelines on hazardous drugs. Am J Health-Syst Pharm 2006; 63: 1172-93.

16.

Gallant C. , Bussières JF , Plante R. , Bertrand G. , Léonard M. , Goyer N. et al. Guide de prévention - Manipulation sécuritaire des médicaments dangereux - ASSTSAS, Montréal, QC. ISBN-978-289618-015-8, 2008, 158 pages.

17.

Bussières J. , Sessink PJ , Prot-Labarthe S. , Larocque D. Évaluation de l'exposition professionnelle aux antinéoplasiques dans une unité de pharmacie hospitalière. Archives des Maladies Professionnelles 2006; 67(6): 880-88.

18.

Larson RR , Khazaeli MB , Dillon HK Monitoring method for surface contamination caused by selected antineoplastic agents. Am J Health Syst Pharm 2002; 59(3): 270-77.

19.

Vandenbroucke J. , Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Practice 2001; 6: 146-52.

20.

Schmaus G. , Schierl R. , Funck S. Monitoring surface contamination by antineoplastic drug using gas chromatography-mass spectrometry and voltametry. Am J Health Sys Pharm 2002; 59: 956-61.

21.

Crauste-Manciet S. , Sessink PJ , Ferrari S. , Jomier JY , Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005; 49(7): 619-28.

22.

Hedmer M. , Tinnerberg H. , Axmon A. , Jönsson BA Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 2007; 81(7): 899-911.

23.

Harrison BR , Peters BG , Bing MR Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health Syst Pharm 2006; 63(18): 1736-44.

24.

Wick C. , Slawson MH , Jorgenson JA , Tyler LS Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Heath Syst Pharm 2003; 60: 2314-20.

25.

Spivey S. , Connor TH Determination of sources of workplace contamination with antineoplastic drugs and comparison of conventional IV drug preparation versus a closed system . Hosp Pharm 2003; 38: 135-39.

26.

Ros JJ , Simons KA , Verzul JM et al. Practical applications of a validated method of analysis for the detection of traces of cyclophosphamide on injection bottles and at oncological outpatient center. Ziekenhuisfarmacie 1997 ; 13: 168-71; (In Dutch).

27.

Hepp R. , Gentschew G. External contamination of commercially available cytotoxic drugs. Krankenhauspharmazie 1998; 19: 22-7; (In German).

28.

Paul H. , Baumann L. , Artelt S. et al. Umgebungskontrolle auf contamination mit zytostatika: nachweis von platin auf oberflächen in räumlicheiten mit zentraler ytostatikaherstelling . Krankenhauspharmazie 1998; 4: 181-86.

29.

Delporte JP , Chenoix P. , Hubert PH Chemical contamination of the primary packaging of 5-fluorouracil RTU solutions commercially available on the Belgian market. Eur Hosp Pharm 1999; 5: 119-21.

30.

Nygren O. , Gustavsson B. , Ström L. et al. Cisplatin contamination observed on the outside of drug vials . Ann Occup Hyg 2002; 46: 555-57.

31.

Favier B. , Gilles L. , Ardiet C. et al. External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. J Oncol Pharm Pract 2003; 9: 15-20.

32.

Mason HJ , Morton J. , Garfitt SJ et al. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg 2003 ; 47: 681-5.

33.

Funck von S. , Schierl R. Sicherheit bei der zytostatikahersatellung . Dtsch Apoth Ztg 2004; 10: 1089-94.

34.

Wilken A. Boebachtungen zur auβenkontamination der primärvpackungen von zytostatika . Krankenhauspharmazie 1997; 1: 37-39.

35.

Bussières JF , Théorêt Y. , Prot-Labarthe S. , Larocque D. A one year pilot study to monitor surface contamination by hazardous drugs in a hemato-oncology pharmacy satellite. Am J Health-Syst Pharm 2007; 64: 531-35.

36.

Connor TH , Anderson RW , Sessink PJ , Spivey SM Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health Syst Pharm 2002; 59: 68-72.

37.

Sessink PJM , Rolf M-AE , Ryden NS Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm 1999; 34: 1311-17.

38.

Tans B. , Willems I. Comparative contamiantion study with cyclophosphamide, fluouracil and ifosfamide standard technique versus a proprietary closed-handling system. J Oncol Pharm Pract 2004; 10: 217-23.

39.

Gustavsson B. Evaluation of a technetium assay for monitoring of occupational exposure to cytotoxic drugs. J Oncol Pharm Pract 1997; 3: 46.

40.

Nygren O. , Gustavsson B. , Strom L. , Eriksson R. , Jarneborn L. , Friberg A. Exposure to anti-cancer drugs preparation and administration. Investigations of an open and closed system. J Environ Monit 2002; 4: 739-42.

41.

United States Pharmacopeia (USP). USP Guidebook to Pharmaceutical Compounding-Sterile Preparations, Chapter 797, http://www.usp.org/products/797Guidebook/ visited on June 17

Evaluation of surface contamination in a hospital hematology—oncology pharmacy

Abstract

Keywords

Get full access to this article

References